1. Introduction {#s0005}
===============

Bile pigments (BPs) such as bilirubin (BR) and biliverdin (BV) are tetrapyrrolic, dicarboxylic compounds derived from the enzymatic heme degradation. They are distributed throughout the body and thus could play an essential role in systemic and tissue-specific health promotion. Numerous studies have identified anti-mutagenic and anti-oxidative activity of specific tetrapyrroles (TPs) in vitro ([@b0005; @b0040]). In vivo data also demonstrate disease prevention through vasoprotection, inhibition of inflammation and anti-oxidant activity ([@b0030; @b0090]). Multiple underlying mechanisms of anti-genotoxic action have been hypothesised but remain to be confirmed. Surprisingly, no publication has focused on quantifying cellular BP absorption which could form a fundamental basis for intracellular action. Therefore, we aimed to quantify the absorption of BR, BV and conjugated BR (ditaurate; BRDT) into two distinct strains of *Salmonella typhimurium* (*S. typhimurium*) via HPLC analyses. It was hypothesised that BPs would be absorbed in a dose-dependent manner into bacteria, and that extracellular (plate) and intracellular (absorbed) BP concentrations would broadly protect against genotoxicity mediated by various mutagens.

2. Materials and methods {#s0010}
========================

2.1. *Salmonella* reverse mutation assay {#s0015}
----------------------------------------

The *Salmonella* reverse mutation assay is an in vitro test assessing the mutagenic potential of chemicals. Bacterial wild-type reversion in the presence of mutagens, allowing growth and colony formation represents its fundamental, technical basis. Experiments were conducted as previously published ([@b0085]), and included 48 h of BP incubation at 37 °C. In some assays, S9 liver homogenate (S9 microsomal fraction from Aroclor-treated rats) was used as an enzymatic activation system. Bile pigment concentrations were tested in triplicate, negative/positive controls were tested in each assay (*n* = 6). Experiments were repeated again on a different day and results were then pooled (*n* = 6 minimum).

### 2.1.1. Bacterial strains {#s0020}

Two strains of *S. typhimurium* were tested: *TA102*, susceptible to oxidative damage, reverts by cross-linking agents, *TA98* detects frame-shift mutations and base-pair deletions ([@b0095]). Strains were kindly provided by Dr. Bruce N. Ames and were attested to their genetic integrity and spontaneous mutation rate ([@b0095]) in our laboratory.

### 2.1.2. Chemicals {#s0025}

Unconjugated bilirubin 1Xα (CAS\# 635-65-4), conjugated bilirubin (ditaurate; CAS\# 635-65-4) and biliverdin 1Xα (CAS\# 55482-27-4) were purchased from Frontier Scientific Europe, UK. Chemical structures can be found online ([Supplementary material 1](#s0075){ref-type="sec"})*.* Pigment purity (\>98%) and solubility were measured using HPLC and spectrophotometry. The S9 liver homogenate was obtained from MP Biomedicals, France. All other reagents and mutagens were purchased from Sigma Aldrich, Austria (unless otherwise noted), were of the highest analytical grade available, and stored according to instructions. Bile pigment solutions were prepared in DMSO, protected from light, and used immediately. Composition and preparation of all necessary solutions can be found elsewhere ([@b0040]). To assess different possibilities of anti-genotoxic action (e.g., structural interactions, radical scavenging, complex formation), four different mutagens were applied at their respective appropriate concentrations ([Table 1](#t0005){ref-type="table"}): 2,4,7-trinitro-9H-fluoren-9-one (J & K Ltd., China; TNFone), *tertiary*-butyl hydroperoxide (Merck; *t-*BOOH), aflatoxin B1 (AfB1) and 2-amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine (Toronto Research Chemicals, Canada; PhIP).

### 2.1.3. Bile pigment sample preparation for the *Salmonella* reverse mutation assay {#s0030}

Based on preceding investigations ([@b0040]), BRDT and BV were tested at concentrations of 0.01, 0.05, 0.1, 0.5, 1 and 2 μmol/plate (equals 3.4, 17.2, 34.5, 172.4, 349 and 689.6 μM). Unconjugated BR was tested over a range of five doses including: 0.01, 0.05, 0.1, 0.5 and 0.75 μmol/plate (equals 258.6 μM). Maximum BP plate concentrations had been ascertained by (1) testing the maximum amount of DMSO that did not result in bacterial cytotoxicity (200 μl/plate) and (2) by the respective maximum solubility of each test compound (spectrophotometric supernatant analysis: BR, BRDT: 455 nm; BV: 380 nm), read on a Perkin Elmer Lambda 2 UV/VIS spectrophotometer after high-speed centrifugation.

2.2. Sample preparation for HPLC analyses {#s0035}
-----------------------------------------

Briefly, *S. typhimurium* colonies (⩾1 mm in diameter) were collected from agar plates, and were lysed for 30 min in 40 μl of isocratic mobile phase (950 ml HPLC-grade methanol, 50 ml HPLC-grade water, 24.2 g n-dioctylamine and 6.01 g glacial acetic acid per litre). Supernatants were diluted at 1:4, and injected (50 μl) into a Hitachi HPLC, equipped with a Shimadzu SPD-M20A detector, and a C18 reverse phase column (5micron, 250 × 4.6 m) ([@b0020; @b0030]). Oven temperature was set at 35 °C, column pressure at 140 bar. Sixteen BP standards were run, ranging from 500 to 0.01 μM. The method's detection limit (LOD) was calculated at 18 nM. Photographs of bacterial colonies can be found online ([Supplementary material 2](#s0075){ref-type="sec"})*.*

2.3. Measurement of total protein content {#s0040}
-----------------------------------------

As a reference parameter for bacterial BP absorption, the total protein content in each diluted sample was measured photometrically ([@b0015]). Bile pigment concentrations were then expressed as nmol/mg total protein.

2.4. Statistical analyses {#s0045}
-------------------------

Data were analysed using SPSS 17.0. A *p-*value ⩽0.05 was considered significant. Data were tested for normal distribution using the Kolmogorov--Smirnov test. Parametric statistical analysis (one-way ANOVA) and the *post hoc* Scheffé test were performed on normally distributed, and corresponding non-parametric tests (Kruskal--Wallis H-test, Dunn's *post hoc* test) on skewed data. Relationships between (1) BP bacterial absorption and plate concentrations; (2) BP bacterial absorption and anti-genotoxic effects; and (3) between BP plate concentrations and anti-mutagenicity were determined by performing bivariate correlations (Pearson or Spearman for parametric and non-parametric data, respectively).

3. Results {#s0050}
==========

HPLC analyses showed significant concentration-dependent BP absorption from agar plates, which was independent of strain, test condition (± S9) and the applied mutagen ([Table 1](#t0005){ref-type="table"}). Furthermore, anti-mutagenic effects of all BPs against all tested mutagens were observed ([Table 2](#t0010){ref-type="table"}).

The relationships between BP plate concentrations, bacterial BP absorption and observed anti-mutagenic effects are shown in [Fig. 1](#f0005){ref-type="fig"}A--C and in [Supplementary material 3](#s0075){ref-type="sec"}. Significant inverse relationships were found between BR plate concentrations in strains *TA98* and *TA102* and anti-mutagenic action against TNFone, as well as between BV plate concentration and PhIP mutagenesis in *TA98* ([Fig. 1](#f0005){ref-type="fig"}A--C). A typical chromatogram showing BR absorption into strain *TA98* is shown in [Fig. 2](#f0010){ref-type="fig"}. Furthermore, significant correlations between pigment plate concentrations and anti-genotoxicity were found for all test conditions ([Table 2](#t0010){ref-type="table"}), indicating a stronger concentration-dependent anti-mutagenic effect based on extracellular (vs. intracellular) BP concentration. Interestingly, the anti-mutagenic effects of BR and BV were most strongly dependent on the bacterial BP absorption exclusively in strain *TA98* ([Table 2](#t0010){ref-type="table"}).

An entirely novel observation was also made in that the obtained HPLC spectra (*not shown*) suggest appearance of BR in plates supplemented with BV, which could imply biliverdin reductase activity in *S. typhimurium.* The ratio of BV to BR (BV:BR) bacterial concentrations calculated from HPLC chromatograms (at 1 μmol/plate BV) approximated 4.4:1 in *TA98* and 9.6:1 in *TA102.*

4. Discussion {#s0055}
=============

This study is the first to report on bacterial BP absorption and its relationship with observed anti-mutagenic effects. When exposed to mutagens, extracellular (plate) BP concentrations negatively correlated with genotoxicity. Furthermore, testing in *TA98* revealed that BV and BR absorption was more strongly related with anti-mutagenesis, when compared to the anti-mutagenic effect relative to plate concentrations.

Previous reports refer to the ability of BPs to act in an anti-oxidant and anti-genotoxic manner in vitro ([@b0005; @b0040]) and in vivo ([@b0010; @b0055]). Vastly unclear to date however, are the underlying mechanisms of anti-genoxic action. In this context mainly electron scavenging or hydrogen donating capacities ([@b0080]) and structural interactions between BPs and mutagens ([@b0050]) are discussed. However, data on cellular compound absorption are lacking and so far only one recent report on enzymatic BRDT reduction in bacteria ([@b0120]) exists. Therefore, we explored whether bacterial BP absorption was more closely related to anti-mutagenesis compared to extracellular BP concentrations around *S. typhimurium* experiencing genotoxic stress.

In this study, physiologically relevant concentrations of BPs were tested. Un-/conjugated BR is found in the blood, the liver, the intestine (where about 70% are recycled via the enterohepatic cycle), and the urinary tract. In these compartments BR is further metabolised, recycled and/or excreted ([@b0070]). The liver and gut, which are sites of BP accumulation, are at particular risk of genotoxicity due to the absorption, metabolism ([@b0045; @b0100]) and excretion of mutagens. The abundance of BPs within these organs suggests BPs could exert physiological protection against DNA damage specifically at these sites.

Interestingly, BR and BV absorption strongly protected against frame-shift mutation in the *TA98* strain. This mutation represents an important mechanism of pathogenesis in gastric and colorectal cancers ([@b0065]). We speculate that the affinity of BPs to protect against frame-shift mutation, might partly explain the protective relationship between serum BR levels and colorectal cancer in vivo ([@b0110]). It should be emphasised, however, that BPs do protect against oxidative and frame-shift mutation when present extracellularly, indicating a clear role for BPs in neutralising mutagens before entering cells. Furthermore, it should be noted that BR causes apoptosis in cancer cells in vitro ([@b0060]), providing an additional mechanism for chemoprevention. These data further emphasise the importance of therapeutically elevating BR concentrations for the prevention of cardiovascular disease and cancer ([@b0090]). Reports to indicate that BV and BRDT are readily absorbed across cultured enterocytes ([@b0025]) support this theory. These data confirm that potential anti-mutagenic BP effects in vivo could be induced by increasing concentrations in the gut lumen ([@b0035]) where food-borne mutagens are found, or by increasing blood BP content in vivo to impart protection from DNA damage ([@b0125]). Although the results of these in vitro experiments cannot be directly extrapolated to in vivo settings, the results suggest BPs in the extracellular milieu (e.g., in the gut lumen/blood) could play a key role in cellular protection, by intercepting mutagens before they arrive at their site of action (e.g., DNA).
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![(A--C) Relationship between bacterial BP absorption and observed anti-mutagenic effects against different mutagens; (A) BR in strain *TA98* with TNFone, (B) BR in strain *TA102* with TNFone, (C) BV in strain *TA98* with PhIP and with S9.](gr1){#f0005}

![Chromatogram of BR (with TNFone) in *Salmonella TA98* colonies.](gr2){#f0010}

###### 

Correlations between BP plate concentrations and bacterial pigment absorption in *Salmonella* strains *TA98* and *TA102* ("availability-based absorption").

  -------------------------------------------------------------------------------------------------
  Compound   Strain    Mutagen conc. \[mol/plate\]   S9   Correlation (r)\
                                                          BP absorption  × BP plate conc.
  ---------- --------- ----------------------------- ---- -----------------------------------------
  BR         *TA98*    TNFone, 0.3 × 10^−6^          −    0.693[⁎⁎](#tblfn1){ref-type="table-fn"}

  BR         *TA102*   TNFone, 0.2 × 10^−7^          −    0.972[⁎⁎](#tblfn1){ref-type="table-fn"}

  BR         *TA98*    PhIP, 0.1 × 10^−7^            \+   0.687[⁎⁎](#tblfn1){ref-type="table-fn"}

  BR         *TA98*    AfB1, 0.8 × 10^−7^            \+   0.982[⁎⁎](#tblfn1){ref-type="table-fn"}

  BR         *TA102*   *t-*BOOH, 0.75 × 10^−6^       −    0.691[⁎⁎](#tblfn1){ref-type="table-fn"}

  BV         *TA98*    PhIP, 0.1 × 10^−7^            \+   0.949[⁎⁎](#tblfn1){ref-type="table-fn"}

  BV         *TA98*    AfB1, 0.8 × 10^−7^            \+   0.972[⁎⁎](#tblfn1){ref-type="table-fn"}

  BV         *TA102*   AfB1, 0.24 × 10^−6^           \+   0.949[⁎⁎](#tblfn1){ref-type="table-fn"}

  BV         *TA102*   *t-*BOOH, 0.75 × 10^−6^       −    0.949[⁎⁎](#tblfn1){ref-type="table-fn"}

  BV         *TA102*   *t-*BOOH, 0.75 × 10^−6^       \+   0.949[⁎⁎](#tblfn1){ref-type="table-fn"}

  BRDT       *TA98*    PhIP, 0.1 × 10^−7^            \+   0.885[⁎⁎](#tblfn1){ref-type="table-fn"}

  BRDT       *TA102*   AfB1, 0.24 × 10^−6^           \+   0.972[⁎⁎](#tblfn1){ref-type="table-fn"}

  BRDT       *TA102*   *t-*BOOH, 0.75 × 10^−6^       −    0.878[⁎](#tblfn2){ref-type="table-fn"}

  BRDT       *TA102*   *t-*BOOH, 0.75 × 10^−6^       \+   0.814[⁎⁎](#tblfn1){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------

S9: metabolic activation system (microsomal fraction from Aroclor-treated rats); BP: bile pigment; BR: unconjugated bilirubin; BV: biliverdin; BRDT: bilirubin ditaurate; TNFone: 2,4,7-trinitro-9H-fluoren-9-one; PhIP: 2-amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine; AfB1: aflatoxin B1; *t-*BOOH: *tertiary* butyl hydroperoxide.

Significant on *p *⩽ 0.01.

Significant on *p *⩽ 0.05.

###### 

Correlations between BP plate concentrations or bacterial BP absorption, respectively, and anti-mutagenic effects in *Salmonella* strains *TA98* and *TA102* ("availability-based anti-mutagenic effects" and "absorption-based anti-mutagenic effects").

  Compound   Strain    Mutagen conc. \[mol/plate\]   S9   Correlation (r) BP plate conc. x anti-mut. effects   Correlation (r) BP absorption x anti-mut. effects
  ---------- --------- ----------------------------- ---- ---------------------------------------------------- ---------------------------------------------------
  BR         *TA98*    TNFone, 0.3 × 10^−6^          −    −0.794[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.938[⁎⁎](#tblfn3){ref-type="table-fn"}
  BR         *TA102*   TNFone, 0.2 × 10^−7^          −    −0.682[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.639[⁎⁎](#tblfn3){ref-type="table-fn"}
  BV         *TA102*   TNFone, 0.2 × 10^−7^          −    −0.493[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.124
  BV         *TA98*    PhIP, 0.1 × 10^−7^            \+   −0.927[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.917[⁎⁎](#tblfn3){ref-type="table-fn"}
  BV         *TA98*    AfB1, 0.8 × 10^−7^            \+   −0.473[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.827[⁎⁎](#tblfn3){ref-type="table-fn"}
  BV         *TA102*   AfB1, 0.24 × 10^−6^           \+   −0.601[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.216
  BV         *TA102*   *t-*BOOH, 0.75 × 10^−6^       −    −0.607[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.570
  BRDT       *TA98*    TNFone, 0.3 × 10^−6^          −    −0.475[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.198
  BRDT       *TA102*   TNFone, 0.2 × 10^−7^          −    −0.378[⁎](#tblfn4){ref-type="table-fn"}              −0.203
  BRDT       *TA98*    AfB1, 0.8 × 10^−7^            \+   −0.548[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.665
  BRDT       *TA102*   *t-*BOOH, 0.75 × 10^−6^       −    −0.754[⁎⁎](#tblfn3){ref-type="table-fn"}             −0.481

S9: metabolic activation system (microsomal fraction from Aroclor-treated rats); BP: bile pigment; BR: unconjugated bilirubin; BV: biliverdin; BRDT: bilirubin ditaurate; TNFone: 2,4,7-trinitro-9H-fluoren-9-one; PhIP: 2-amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine; AfB1: aflatoxin B1; *t-*BOOH: *tertiary* butyl hydroperoxide.

Significant on *p *⩽ 0.01.

Significant on *p *⩽ 0.05.
